Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.

The results showed that people who received nivolumab versus placebo: Survived longer before the cancer was detected again, including people who had programmed death ligand-1 (shortened to PD-L1) on their cancer cells. Survived longer before a secondary cancer outside of the urinary tract was detected. Experienced no differences in health-related quality of life (the impact of the treatment on a person's mental and physical health). Had similar side effects to the people who received nivolumab in other studies. : NCT02632409 (ClinicalTrials.gov).